Saltar al contenido
MilliporeSigma
HomeImproved Vaccine Production

Improved Vaccine Production

LEARN HOW WE CAN TAKE YOUR INNOVATION from early phase development to full-scale GMP-manufacturing efficiently, safely, and cost-effectively

Contact us today to discuss your needs with a technical representative.

Fields indicated by an * are required.



Featured Articles

We are committed to partnering with pharmaceutical companies, organizations and other companies to accelerate vaccine development and ultimately increase access globally. Our collaborations with worldwide vaccine developers and researchers include:

  • Leveraging previous efforts at an adenovirus-based vaccine platform for rapid development of a Covid-19 vaccine platform (read more)
  • Building on previous collaborations with the Baylor College of Medicine to optimize production of two Covid-19 vaccine candidates (read more)
  • Joining the DiViNe Consortium in Europe to address low yields and high costs of vaccine purification (read our white paper)
  • Developing optimized purification processes with the International Vaccine Institute (read more)
  • Receiving a grant from the Bill & Melinda Gates Foundation as part of a consortium pursuing a new manufacturing platform that would radically increase vaccine availability and affordability in developing countries (read more)

Contact us today to discuss your needs with a technical representative, and discover new solutions for better, faster, safer vaccine development.



Related Links

Natrix® Q Chromatography Membrane Adsorbers

A breakthrough in membrane chromatography

Read More...

Fractogel® Ion Exchange Chromatography Resins

For Reliable and Effective Protein Purification

Read More...

Benzonase®Endonuclease

Safety Plus Emprove® Expert
DNA and RNA Removal for downstream processing

Read More...

Emprove® Chemicals Portfolio

Confidently fast track your new drug to market

Read More...




Inicie sesión para continuar.

Para seguir leyendo, inicie sesión o cree una cuenta.

¿No tiene una cuenta?